Re-treatment of chronic hepatitis C with consensus interferon

Area of Science:

• Hepatology
• Virology
• Clinical Therapeutics

Background:

• Chronic hepatitis C virus (HCV) infection remains a significant global health concern.
• Previous interferon-based therapies have limited efficacy in non-responders and relapsers.
• Identifying effective retreatment strategies is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the safety and efficacy of a higher dose of consensus interferon (15 mcg) in patients with chronic HCV who failed prior interferon therapy.
• To compare the outcomes of 24-week versus 48-week treatment durations with consensus interferon.
• To assess sustained virologic and biochemical responses in different patient subgroups.

Main Methods:

• A multicenter, open-label, phase 3 study involving 337 patients with chronic HCV.
• Randomization to receive subcutaneous consensus interferon (15 mcg) three times weekly for 24 or 48 weeks.
• Post-treatment observation for an additional 24 weeks with assessment of alanine aminotransferase (ALT) and HCV RNA levels.

Main Results:

• Patients who relapsed after prior interferon therapy showed higher sustained HCV RNA and ALT responses compared to non-responders.
• For relapsers, sustained HCV RNA response rates were 58% (48 weeks) and 28% (24 weeks).
• For non-responders, sustained HCV RNA response rates were 13% (48 weeks) and 5% (24 weeks).
• Higher dose (15 mcg) consensus interferon was well tolerated with no increased side effects.

Conclusions:

• Re-treatment with 15 mcg of consensus interferon is a safe and effective option for chronic HCV patients with prior treatment failure.
• A 48-week treatment duration demonstrated superior sustained response rates compared to 24 weeks.
• This regimen offers a viable therapeutic strategy for difficult-to-treat HCV populations.